typhim vi stungulyf, lausn 25 míkróg/0,5 ml
sanofi pasteur* - salmonella typhi vi antigen - stungulyf, lausn - 25 míkróg/0,5 ml
stilnoct filmuhúðuð tafla 10 mg
sanofi-aventis norge as - zolpidemum tartrat - filmuhúðuð tafla - 10 mg
flagyl leggangastíll 500 mg
sanofi-aventis norge as - metronidazolum inn - leggangastíll - 500 mg
imovane filmuhúðuð tafla 7,5 mg
sanofi-aventis norge as - zopiclonum inn - filmuhúðuð tafla - 7,5 mg
orudis hart forðahylki 100 mg
sanofi-aventis norge as - ketoprofenum inn - hart forðahylki - 100 mg
pentavac stungulyfsstofn og dreifa, dreifa
sanofi pasteur* - filamentous haemagglutinin; poliovirus inactivated type 2; poliovirus inactivated type 3; diphtheria toxoid; tetanus toxoid; poliovirus inactivated type 1; pertussis toxoid; haemophilus influenzae type b - stungulyfsstofn og dreifa, dreifa
solian tafla 200 mg
sanofi-aventis norge as - amisulpridum inn - tafla - 200 mg
solian tafla 50 mg
sanofi-aventis norge as - amisulpridum inn - tafla - 50 mg
repevax stungulyf, dreifa áfyllt sprauta
sanofi pasteur* - tetanus toxoid; diphtheria toxoid; pertussis toxoid; filamentous haemagglutinin; pertussis fimbrial agglutinogens (fim) 2 and 3; pertactin; poliovirus (inactivated) type 1 (mahoney strain); poliovirus (inactivated) type 2 (mef-1 strain); poliovirus (inactivated) type 3 (saukett strain) - stungulyf, dreifa - áfyllt sprauta
aubagio
sanofi winthrop industrie - teriflunomide - margvísleg sclerosis - valdar ónæmisbælandi lyf - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).